Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Rises By 229.0%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 1,311,363 shares, an increase of 229.0% from the June 15th total of 398,648 shares. Approximately 3.2% of the company’s stock are sold short. Based on an average daily trading volume, of 559,861 shares, the days-to-cover ratio is currently 2.3 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its stake in shares of CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares during the last quarter. Vivo Capital LLC lifted its stake in CAMP4 Therapeutics by 8.3% in the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after purchasing an additional 325,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in CAMP4 Therapeutics during the fourth quarter worth about $14,938,000. Adage Capital Partners GP L.L.C. grew its holdings in CAMP4 Therapeutics by 11.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock worth $13,374,000 after purchasing an additional 220,895 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in CAMP4 Therapeutics during the first quarter worth approximately $1,497,000.

CAMP4 Therapeutics Stock Down 1.1%

NASDAQ:CAMP opened at $4.45 on Wednesday. CAMP4 Therapeutics has a twelve month low of $1.32 and a twelve month high of $7.75. The firm has a market capitalization of $231.09 million, a price-to-earnings ratio of -1.89 and a beta of 0.10. The stock’s 50 day moving average price is $4.28 and its two-hundred day moving average price is $4.59.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The company had revenue of $1.29 million during the quarter. As a group, analysts anticipate that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CAMP has been the topic of several research reports. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Leerink Partners boosted their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.36.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.